Recently, we reported a series of donepezil-based piperazine-2-carboxylic acid derivatives, essentially designed as MTDLs anti- Alzheimer's agents, with nanomolar to sub micromolar dual inhibitory activity against acetylcholinesterase and butyrylcholinesterase. Herein, we report the evaluation of selected series of the designed compounds 4(c, d), 5(b, c), 7(a-f), 8(a, b, f), for potential activity against further clinical traits involved in the pathogenesis of Alzheimer's disease (AD). The results revealed compounds 7b and 8f with promising in vitro inhibitory effect against Aβ aggregation (IC50 = 1.15 ± 0.05 and 1.10 ± 0.05 μM, respectively) as compared to the reference drug, curcumin (IC50 = 6.54 ± 0.31 μM). Meanwhile, compounds 7b, 7e and 8f exhibited comparable in vitro inhibitory activity against HDAC1, (IC50 = 0.30 ± 0.01, 0.14 ± 0.01 and 0.15 ± 0.01 μM respectively), relative to the reference drugs SAHA (IC50 = 0.046 ± 0.002 μM) and entinostat, (IC50 = 0.05 ± 0.002 μM). Additionally, the investigated compounds displayed radical scavenging effect comparable to DPPH, and metal chelating ability towards Cu (II) and Zn (II) metals. The neuroprotective characteristics have been established in vivo through several analytical assessments of the potential effects against AlCl3-induced AD, in comparison to donepezil as reference drug. Explicitly, the studies involve behavioural tests, oxidative stress, neuroinflammatory markers, amyloid-beta (Aβ) aggregation, acetylcholine and acetylcholinesterase levels. The results displayed in vivo activity comparable to the reference drug. Docking studies, in the binding sites of Aβ(1–42) peptide (PDB code 1IYT) and HDAC1 (PDB code 4BKX), demonstrate binding modes analogous to that elicited by the native ligands, respectively. These findings confirm of the neuroprotective activity of the designed compounds and establish their validity as MTDLs candidates for further investigation against Alzheimer's disease.